Associate
Candace Walther concentrates on patent litigation, particularly Abbreviated New Drug Application (ANDA) cases, as well as patent prosecution and client counseling. Her technical expertise encompasses biochemistry and microbiology, particularly in the areas of synthetic biology and protein engineering.
Candace represents pharmaceutical patent holders in ANDA litigations arising under the Hatch-Waxman Act. Her litigation experience covers various aspects of trial preparation, including discovery and pre-trial activities. Candace also drafts and prosecutes patent applications, assists in client counseling, and prepares infringement and freedom to operate opinions in a wide range of chemical-related technology areas.
While in law school, Candace worked as a summer associate and law clerk at Finnegan, assisting in litigation matters before federal district courts and with prosecuting patent applications and client counseling. She also worked as a research assistant, conducting research on international and comparative patent law and assisting in the preparation of a study for the United Nations Convention on Biological Diversity. Candace also completed the TI:GER certificate program, where she advised a biomedical engineering Ph.D. student on intellectual property matters, including patentability, freedom-to-operate, and obtaining protection for and commercializing their technology.
During her undergraduate studies, Candace worked in a microbiology and biochemistry lab, where her research focused on synthetic biology and protein engineering in the fields of infectious diseases and drug discovery.
Candace is committed to her pro bono practice and represents honorably discharged veterans before the U.S. Court of Appeals for Veterans Claims.
Rocket Pharmaceuticals, Inc. v. Lexeo Therapeutics, Inc., et al.
Represented Rocket Pharmaceuticals, Inc. in district court litigation involving claims of trade secret misappropriation and breach of contract against individual and corporate defendants and relating to complex treatments for genetic disorders. Successfully opposed motion to dismiss key claims and obtained settlement with all defendants following completion of fact discovery.
1:23-cv-09000, S.D.N.Y., Judges Castel, Aaron
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Trial counsel for Novartis in district court litigation against multiple generics related to KISQALI ®, a blockbuster, breakthrough CDK4/6-inhibitor for the treatment of breast cancer. After a bench trial, the case resulted in a favorable settlement for our client, supporting patent protection at least until 2031.
1:21-cv-00870, D. Del., Judge Hall
At the PTAB Blog
Claim Disclaimer Derails Instituted IPR in Freightcar America Claim Disclaimer Derails Instituted IPR in Freightcar America
May 26, 2026
At the PTAB Blog
USPTO Announces Voluntary Search Disclosure Declarations Initiative for PTAB Proceedings USPTO Announces Voluntary Search Disclosure Declarations Initiative for PTAB Proceedings
November 19, 2025
At the PTAB Blog
Missing Sotera/Tesla Stipulation Dooms Petition on Young Patents in Phison Missing Sotera/Tesla Stipulation Dooms Petition on Young Patents in Phison
July 31, 2025
Articles
Using Contracts As Evidence Of Trade Secret Protection Using Contracts As Evidence Of Trade Secret Protection
December 18, 2024
Law360Articles
Southeast Litigation Update: September 2024 Southeast Litigation Update: September 2024
November 22, 2024
Articles
Southeast Litigation Update: May 2023 Southeast Litigation Update: May 2023
August 17, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.